Dingcheng Gao

Cornell University — United States

Medicine · Health Sciences

27h-index6.8kcitations189works4.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Cells and Metastasis(92), Angiogenesis and VEGF in Cancer(50), RNA modifications and cancer(24), Nuclear Receptors and Signaling(20), MicroRNA in disease regulation(18)

Publications189 total

Oligo-CALL: A next-generation barcoding platform for studying resistance to targeted therapy
Science Advances·2025Open Access
Abstract 2487: LINMAP: A framework for comprehensive cell division lineage reconstruction via molecular barcoding and machine learning
Cancer Research·2025
Abstract 419: Chromosomal instability and oncogene dosage variations underlying KRAS G12C inhibition therapy resistance in lung cancer
Cancer Research·2025
Deficiency of metabolic regulator PKM2 activates the pentose phosphate pathway and generates TCF1+ progenitor CD8+ T cells to improve immunotherapy
Nature Immunology·2024· 27 citedOpen Access
Author response: Targeting ribosome biogenesis as a novel therapeutic approach to overcome EMT-related chemoresistance in breast cancer
2024Open Access
Targeting ribosome biogenesis as a novel therapeutic approach to overcome EMT-related chemoresistance in breast cancer
eLife·2024· 7 citedOpen Access
Author response: Targeting Ribosome Biogenesis as a Novel Therapeutic Approach to Overcome EMT-related Chemoresistance in Breast Cancer
2024Open Access
Targeting Ribosome Biogenesis as a Novel Therapeutic Approach to Overcome EMT-related Chemoresistance in Breast Cancer
2024· 2 citedOpen Access
Charting Single Cell Lineage Dynamics and Mutation Networks via Homing CRISPR
2024· 1 citedOpen Access
Targeting Ribosome Biogenesis as a Novel Therapeutic Approach to Overcome EMT-related Chemoresistance in Breast Cancer
2023· 1 citedOpen Access
Reviewer #3 (Public Review): Targeting Ribosome Biogenesis as a Novel Therapeutic Approach to Overcome EMT-related Chemoresistance in Breast Cancer
2023Open Access
Reviewer #2 (Public Review): Targeting Ribosome Biogenesis as a Novel Therapeutic Approach to Overcome EMT-related Chemoresistance in Breast Cancer
2023Open Access
Reviewer #1 (Public Review): Targeting Ribosome Biogenesis as a Novel Therapeutic Approach to Overcome EMT-related Chemoresistance in Breast Cancer
2023Open Access
Targeting ribosome biogenesis as a novel therapeutic approach to overcome EMT-related chemoresistance in breast cancer
eLife·2023· 9 citedOpen Access
Deficiency of metabolic regulator PKM2 activates the pentose phosphate pathway and generates TCF1+ progenitor CD8+ T cells to improve checkpoint blockade
2023Open Access
Targeting Ribosome Biogenesis as a Novel Therapeutic Approach to Overcome EMT-related Chemoresistance in Breast Cancer
2023· 2 citedOpen Access
Abstract 603: Deficiency of metabolic regulator PKM2 activates the pentose phosphate pathway to generate TCF1+ progenitor CD8+ T cells to improve checkpoint blockade
Cancer Research·2023
Supplementary Figure S10 from Bone Marrow–Derived Gr1<sup>+</sup> Cells Can Generate a Metastasis-Resistant Microenvironment Via Induced Secretion of Thrombospondin-1
2023Open Access
Supplementary Figure S2 from Bone Marrow–Derived Gr1<sup>+</sup> Cells Can Generate a Metastasis-Resistant Microenvironment Via Induced Secretion of Thrombospondin-1
2023Open Access
Supplementary Methods from Bone Marrow–Derived Gr1<sup>+</sup> Cells Can Generate a Metastasis-Resistant Microenvironment Via Induced Secretion of Thrombospondin-1
2023Open Access
page 1 of 10Next →

Frequent Co-authors

Vivek Mittal(36), Nasser K. Altorki(18), Stephen T.C. Wong(13), Sharrell B. Lee(13), Hyejin Choi(12), Yi Ban(12), Jianting Sheng(11), Seongho Ryu(10), Tina El Rayes(7), Linda T. Vahdat(7), Geoffrey J. Markowitz(7), Natasha Joshi(7), Raúl Catena(7), Olivier Elemento(7), Kari Fischer(6), Michael J. Crowley(6), Yue Zou(6), Anna Durrans(5), Robert B. Bednarczyk(5), Yuliang Cao(5)